{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:31:03Z","timestamp":1790836263941,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction\/Aim<\/jats:title>\n                    <jats:p>HLA-B27\/human \u03b22m transgenic rats (B27-rats) develop an inflammatory disorder resembling spondyloarthritis (SpA) with dysregulated IL-10\/IL-17 production by regulatory T cells (Treg). Treg plays a major role in controlling pathogenic inflammatory processes. Interleukin 2 (IL-2), a cytokine which promotes Treg cell survival and function, may thus have therapeutic efficacy in SpA. Here, we tested this hypothesis using a low dose of IL-2 treatment in B27-rat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>B27-rats aged 4 weeks (before disease onset) and nontransgenic (NTG) littermates were administered intraperitoneally recombinant human IL-2 (Sanofi\u00ae; 2,000IU\/injection) or PBS, 3 days per week during 6 weeks. Assessment of treatment effect was performed, based on clinical (weight, diarrhea, arthritis), histological (proximal and distal colon, caecum, ileum and tarsal\/ankle joint) scores, and frequency of Treg in the spleen and lymph nodes (LN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IL-2 administration had no effect on weight gain, either in B27- or NTG-rats. Over the 6 weeks of treatment, the clinical disease score worsened similarly in both IL-2-treated and control groups of B27-rats. The macroscopic and histological evaluation of gut and joints showed marked inflammation in B27-rats; however, no change related to IL-2 treatment was observed. In the B27-rats, the percentage of Treg was moderately increased after IL-2 treatment in the spleen, but neither in mesenteric nor peripheral LN in those rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data demonstrate that a low dose of IL-2 administered before disease onset was moderately effective for boosting Treg but failed to prevent SpA development in B27-rat.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02559-y","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:03:07Z","timestamp":1626411787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of a low-dose IL-2 treatment in HLA-B27 transgenic rat model of spondyloarthritis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-3000","authenticated-orcid":false,"given":"L. M.","family":"Araujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Jouhault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Fert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bouiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chiocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Breban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"issue":"26","key":"2559_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016 Jun 30;374(26):2563\u201374. https:\/\/doi.org\/10.1056\/NEJMra1406182.","journal-title":"N Engl J Med"},{"key":"2559_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1600-065x.1999.tb01317.x","volume":"169","author":"JD Taurog","year":"1999","unstructured":"Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev. 1999 Jun;169:209\u201323. https:\/\/doi.org\/10.1111\/j.1600-065x.1999.tb01317.x.","journal-title":"Immunol Rev"},{"issue":"1","key":"2559_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.33321","volume":"64","author":"S Glatigny","year":"2012","unstructured":"Glatigny S, Fert I, Blaton MA, Lories RJ, Araujo LM, Chiocchia G, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012 Jan;64(1):110\u201320. https:\/\/doi.org\/10.1002\/art.33321.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2559_CR4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38737","volume":"66","author":"LM Araujo","year":"2014","unstructured":"Araujo LM, Fert I, Jouhault Q, Labroqu\u00e8re K, Andrieu M, Chiocchia G, et al. Increased production of interleukin-17 over interleukin-10 by Treg cells implicates inducible costimulator molecule in experimental spondyloarthritis. Arthritis Rheum. 2014 Sep 1;66(9):2412\u201322. https:\/\/doi.org\/10.1002\/art.38737.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2559_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","volume":"13","author":"M Noack","year":"2014","unstructured":"Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014 Jun;13(6):668\u201377. https:\/\/doi.org\/10.1016\/j.autrev.2013.12.004.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2559_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015 May;15(5):283\u201394. https:\/\/doi.org\/10.1038\/nri3823.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2559_CR7","first-page":"67","volume":"9","author":"N Vita","year":"1990","unstructured":"Vita N, Magazin M, Marchese E, Lupker J, Ferrara P. Closely related glycosylation patterns of recombinant human IL-2 expressed in a CHO cell line and natural IL-2. Lymphokine Res. 1990;9(1):67\u201379.","journal-title":"Lymphokine Res"},{"key":"2559_CR8","doi-asserted-by":"publisher","unstructured":"Garzon FT, Salas M, Berger MR, Kirchner H. Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma. J Cancer Res Clin Oncol 1986;111(1):79\u201381, 1, DOI: https:\/\/doi.org\/10.1007\/BF00402782.","DOI":"10.1007\/BF00402782"},{"issue":"2","key":"2559_CR9","first-page":"161","volume":"9","author":"V Bertrand","year":"1998","unstructured":"Bertrand V, Qu\u00e9r\u00e9 S, Guimbaud R, Sogni P, Chauvelot-Moachon L, Tulliez M, et al. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human 2-microglobulin. Eur Cytokine Netw. 1998;9(2):161\u201370.","journal-title":"Eur Cytokine Netw"},{"issue":"6","key":"2559_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","volume":"75","author":"R Wang","year":"2016","unstructured":"Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207677.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2559_CR11","doi-asserted-by":"publisher","first-page":"R335","DOI":"10.1186\/ar1192","volume":"6","author":"D Cao","year":"2004","unstructured":"Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstr\u00f6m V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6(4):R335\u201346. https:\/\/doi.org\/10.1186\/ar1192.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2559_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/icb.2015.90","volume":"94","author":"L Ye","year":"2016","unstructured":"Ye L, Goodall JC, Zhang L, Putintseva EV, Lam B, Jiang L, et al. TCR usage, gene expression and function of two distinct FOXP3(+)Treg subsets within CD4(+)CD25(hi) T cells identified by expression of CD39 and CD45RO. Immunol Cell Biol. 2016 Mar;94(3):293\u2013305. https:\/\/doi.org\/10.1038\/icb.2015.90.","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"2559_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jbspin.2015.03.003","volume":"82","author":"H-T Liao","year":"2015","unstructured":"Liao H-T, Lin Y-F, Tsai C-Y, Chou C-T. Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment. Joint Bone Spine. 2015 Dec;82(6):423\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2015.03.003.","journal-title":"Joint Bone Spine"},{"issue":"12","key":"2559_CR14","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1002\/art.27699","volume":"62","author":"F Ciccia","year":"2010","unstructured":"Ciccia F, Accardo-Palumbo A, Giardina A, Di Maggio P, Principato A, Bombardieri M, et al. Expansion of intestinal CD4+CD25high Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum. 2010 Dec 1;62(12):3625\u201334. https:\/\/doi.org\/10.1002\/art.27699.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2559_CR15","doi-asserted-by":"publisher","first-page":"37559","DOI":"10.1038\/srep37559","volume":"30","author":"H Guo","year":"2016","unstructured":"Guo H, Zheng M, Zhang K, Yang F, Zhang X, Han Q, et al. Functional defects in CD4+ CD25high FoxP3+ regulatory cells in ankylosing spondylitis. Sci Rep. 2016;30(6):37559.","journal-title":"Sci Rep"},{"issue":"2","key":"2559_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, Soufi KE, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214229.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2559_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295\u2013305. https:\/\/doi.org\/10.1016\/S2213-8587(13)70113-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2559_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, Six A, D\u00e9rian N, Chaara W, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015 Apr;58:48\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2015.01.001.","journal-title":"J Autoimmun"},{"issue":"15","key":"2559_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015094","volume":"98","author":"H An","year":"2019","unstructured":"An H, Li X, Li F, Gao C, Li X, Luo J. The absolute counts of peripheral T lymphocyte subsets in patient with ankylosing spondylitis and the effect of low-dose interleukin-2. Medicine (Baltimore). 2019 Apr;98(15):e15094. https:\/\/doi.org\/10.1097\/MD.0000000000015094.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2559_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcmgh.2019.05.001","volume":"8","author":"JA Goettel","year":"2019","unstructured":"Goettel JA, Kotlarz D, Emani R, Canavan JB, Konnikova L, Illig D, et al. Low-dose interleukin-2 ameliorates colitis in a preclinical humanized mouse model. Cell Mol Gastroenterol Hepatol. 2019;8(2):193\u20135. https:\/\/doi.org\/10.1016\/j.jcmgh.2019.05.001.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"2559_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/iid3.364","volume":"8","author":"H Sun","year":"2020","unstructured":"Sun H, Zhao Y, Wang K, Zhu L, Dong J, Zhao J, et al. Low dose IL-2 suppress osteoclastogenesis in collagen-induced arthritis via JNK dependent pathway. Immun Inflamm Dis. 2020 Oct 24;8(4):727\u201335. https:\/\/doi.org\/10.1002\/iid3.364.","journal-title":"Immun Inflamm Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02559-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:09:09Z","timestamp":1626412149000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02559-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2559"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02559-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the institutional ethical committee (APAFIS-8910).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}